“Designing of heterocyclic compounds as promising VEGFR2 tyrosine kinase inhibitors: An Insilico analysis”, Int. J. Pharm. Sci. Drug Res., vol. 13, no. 6, pp. 685–698, Nov. 2021, doi: 10.25004/IJPSDR.2021.130612.